Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab + lenvatinib conversion therapy in advanced hepatocellular carcinoma
ChiCTR2400085727Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Jun 2024
- Modality
- Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab and lenvatinib in hepatocellular carcinoma (HCC) and liver cancer, sponsored by Liaoning Province Cancer Hospital. Primary endpoint: objective response rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
envafolimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on ChiCTR2400085727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085727.